PL2961732T3 - Sulfamoilo-aryloamidy i ich stosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B - Google Patents

Sulfamoilo-aryloamidy i ich stosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B

Info

Publication number
PL2961732T3
PL2961732T3 PL14707372T PL14707372T PL2961732T3 PL 2961732 T3 PL2961732 T3 PL 2961732T3 PL 14707372 T PL14707372 T PL 14707372T PL 14707372 T PL14707372 T PL 14707372T PL 2961732 T3 PL2961732 T3 PL 2961732T3
Authority
PL
Poland
Prior art keywords
arylamides
sulfamoyl
medicaments
hepatitis
treatment
Prior art date
Application number
PL14707372T
Other languages
English (en)
Polish (pl)
Inventor
Koen Vandyck
Stefaan Julien Last
Pierre Jean-Marie Bernard Raboisson
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of PL2961732T3 publication Critical patent/PL2961732T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL14707372T 2013-02-28 2014-02-27 Sulfamoilo-aryloamidy i ich stosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B PL2961732T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13157232 2013-02-28
EP13170069 2013-05-31

Publications (1)

Publication Number Publication Date
PL2961732T3 true PL2961732T3 (pl) 2017-09-29

Family

ID=50190432

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14707372T PL2961732T3 (pl) 2013-02-28 2014-02-27 Sulfamoilo-aryloamidy i ich stosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B

Country Status (18)

Country Link
US (2) US10125094B2 (2)
EP (1) EP2961732B1 (2)
JP (1) JP6466348B2 (2)
CN (1) CN105189453B (2)
AU (1) AU2014222641B2 (2)
BR (1) BR112015020242A2 (2)
CA (1) CA2899706C (2)
DK (1) DK2961732T3 (2)
EA (1) EA027194B1 (2)
ES (1) ES2628953T3 (2)
HR (1) HRP20170945T1 (2)
HU (1) HUE034820T2 (2)
IL (1) IL240213A (2)
MX (1) MX366123B (2)
PL (1) PL2961732T3 (2)
PT (1) PT2961732T (2)
SI (1) SI2961732T1 (2)
WO (1) WO2014131847A1 (2)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014015197A8 (pt) 2011-12-21 2017-06-13 Novira Therapeutics Inc agentes antivirais de hepatite b
KR102271574B1 (ko) 2012-08-28 2021-07-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
WO2014131847A1 (en) 2013-02-28 2014-09-04 Janssen R&D Ireland Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
MX353412B (es) 2013-04-03 2018-01-10 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
DK2997019T3 (en) 2013-05-17 2018-12-03 Janssen Sciences Ireland Uc SULFAMOYLTHIOPHENAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
TWI733288B (zh) 2013-05-17 2021-07-11 愛爾蘭商健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
HRP20180791T1 (hr) 2013-07-25 2018-09-07 Janssen Sciences Ireland Uc Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
CA2923712C (en) 2013-10-23 2021-11-02 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
CA2936947A1 (en) 2014-02-05 2015-08-13 Novira Therapeutics, Inc. Combination therapy for treatment of hbv infections
TW201620893A (zh) 2014-02-06 2016-06-16 健生科學愛爾蘭無限公司 磺醯胺基吡咯醯胺衍生物及其用作治療ｂ型肝炎之醫藥品的用途
ES2748029T3 (es) 2014-03-13 2020-03-12 Univ Indiana Res & Tech Corp Moduladores alostéricos de proteína núcleo de hepatitis B
CN107406378A (zh) * 2014-12-02 2017-11-28 诺维拉治疗公司 用于hbv治疗的硫化烷基化合物和吡啶类反式磺酰胺化合物
US9765050B2 (en) * 2014-12-30 2017-09-19 Novira Therapeutics, Inc. Pyridyl reverse sulfonamides for HBV treatment
US9670205B2 (en) 2015-03-04 2017-06-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
JP2018510159A (ja) 2015-03-19 2018-04-12 ノヴィラ・セラピューティクス・インコーポレイテッド アゾカン及びアゾナン誘導体及びｂ型肝炎感染症の治療法
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US20210292327A1 (en) 2015-08-26 2021-09-23 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
TWI721016B (zh) 2015-09-15 2021-03-11 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
TW201718496A (zh) 2015-09-29 2017-06-01 諾維拉治療公司 B型肝炎抗病毒劑之晶型
AU2017248828A1 (en) 2016-04-15 2018-11-01 Janssen Sciences Ireland Uc Combinations and methods comprising a capsid assembly inhibitor
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
EA201892375A1 (ru) 2016-05-27 2019-08-30 Джилид Сайэнс, Инк. Способы лечения инфекций, вызываемых вирусом гепатита b
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
AU2017318601B2 (en) 2016-09-02 2020-09-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
AU2017326356A1 (en) 2016-09-15 2019-04-11 Assembly Biosciences, Inc. Hepatitis B core protein modulators
KR20230010826A (ko) 2016-10-14 2023-01-19 프리시젼 바이오사이언시스 인코포레이티드 B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
SG11201902944TA (en) 2016-11-07 2019-05-30 Arbutus Biopharma Corp Substituted pyridinone-containing tricyclic compounds, and methods using same
WO2018086530A1 (zh) * 2016-11-08 2018-05-17 正大天晴药业集团股份有限公司 作为cccDNA抑制剂的磺酰胺类化合物
TW202510891A (zh) 2017-01-31 2025-03-16 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
UY37581A (es) 2017-02-02 2018-08-31 Gilead Sciences Inc Compuestos para el tratamiento de la infección por virus de la hepatitis b
US10654837B2 (en) * 2017-02-07 2020-05-19 Janssen Pharmaceutica Nv Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis
CA3055194A1 (en) 2017-03-02 2018-09-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
MA49014A (fr) 2017-03-21 2020-02-05 Arbutus Biopharma Corp Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CN111051305A (zh) 2017-08-22 2020-04-21 吉利德科学公司 治疗性杂环化合物
WO2019123339A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN108395389A (zh) * 2018-01-29 2018-08-14 江苏佳麦化工有限公司 制备3-氯磺酰苯甲酰氯的方法
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
MX2020009531A (es) 2018-03-14 2020-10-05 Janssen Sciences Ireland Unlimited Co Regimen posologico del modulador del ensamblaje de la capside.
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
US11186579B2 (en) 2018-07-06 2021-11-30 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
AU2019297362B2 (en) 2018-07-06 2022-05-26 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
SG11202012425QA (en) 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
TWI826492B (zh) 2018-07-27 2023-12-21 加拿大商愛彼特生物製藥公司 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
CA3117449A1 (en) 2018-10-22 2020-04-30 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US20210395751A1 (en) 2018-10-31 2021-12-23 The University Of Sydney Compositions and methods for treating viral infections
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
TW202415643A (zh) 2018-12-12 2024-04-16 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
WO2020169784A1 (en) 2019-02-22 2020-08-27 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3934757B1 (en) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
AR119732A1 (es) 2019-05-06 2022-01-05 Janssen Sciences Ireland Unlimited Co Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
BR112021023622A2 (pt) 2019-05-24 2022-04-19 Assembly Biosciences Inc Composições farmaceuticas para o tratamento de hbv
CA3140708A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
DK4037708T3 (da) 2019-09-30 2024-09-30 Gilead Sciences Inc HBV-vacciner og fremgangsmåder til at behandle HBV
DK4069729T3 (da) 2019-12-06 2025-04-07 Prec Biosciences Inc Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CN121248511A (zh) 2020-04-22 2026-01-02 组装生物科学股份有限公司 用于治疗hbv的5元杂芳基甲酰胺化合物
WO2021216660A1 (en) 2020-04-22 2021-10-28 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2021216661A1 (en) 2020-04-22 2021-10-28 Assembly Biosciences, Inc. Pyrazole carboxamide compounds for treatment of hbv
WO2021216642A1 (en) 2020-04-22 2021-10-28 Assembly Biosciences, Inc. Pyrazole carboxamide compounds for treatment of hbv
EP4192474B1 (en) 2020-08-07 2025-09-10 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
CN114989049B (zh) * 2021-06-11 2023-06-27 四川大学华西医院 Vif抑制剂及其在制备抗HIV药物中的用途
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
JP7686091B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
AU2022299051B2 (en) 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023069545A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023069547A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023069544A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
US20250163009A1 (en) 2022-02-25 2025-05-22 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164186A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164179A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164181A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2025043094A1 (en) 2023-08-23 2025-02-27 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240243A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
WO2026038156A1 (en) 2024-08-15 2026-02-19 Assembly Biosciences, Inc. Novel crystalline forms

Family Cites Families (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3843662A (en) 1971-12-09 1974-10-22 Pfizer 2-halo-5-(substituted piperidino sulfonyl)benzoic acids
AU1508183A (en) 1982-06-04 1983-12-08 Beecham Group Plc Benzamide and anilide derivatives of 8-azabicyclo-(3.2.1)- -octane
EP0135545A1 (en) 1983-02-19 1985-04-03 Beecham Group Plc Azabicycloalkyl benzamide and anilide derivatives
JPS62142164A (ja) 1985-12-13 1987-06-25 Ishihara Sangyo Kaisha Ltd ４，５−ジクロロイミダゾ−ル系化合物及びそれらを含有する有害生物防除剤
IN164880B (2) 1986-01-30 1989-06-24 Ishihara Sangyo Kaisha
US5272167A (en) 1986-12-10 1993-12-21 Schering Corporation Pharmaceutically active compounds
CA1339133C (en) 1987-03-13 1997-07-29 Rikuo Nasu Imidazole compounds and biocidal composition comprising the same for controlling harmful organisms
US5571821A (en) 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
GB8904174D0 (en) 1989-02-23 1989-04-05 British Bio Technology Compounds
US4962101A (en) 1989-08-21 1990-10-09 Merck & Co., Inc. 2-(Heterocyclylalkyl)phenyl carbapenem antibacterial agents
GB9023082D0 (en) 1990-10-24 1990-12-05 Schering Agrochemicals Ltd Fungicides
GB9109557D0 (en) 1991-05-02 1991-06-26 Wellcome Found Chemical compounds
US5308826A (en) 1993-04-22 1994-05-03 Zeneca Limited Herbicidal 4-substituted pyridyl-3-carbinols
GB9405347D0 (en) 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
DE69530081T2 (de) 1994-05-27 2003-12-24 James Black Foundation Ltd., London Gastrin- und cck-antagonisten
US5795907A (en) 1994-05-27 1998-08-18 James Black Foundation Limited Gastin and CCK receptor ligands
US5763618A (en) 1995-05-12 1998-06-09 Konica Corporation Manufacturing method of sulfides
US5723411A (en) 1995-10-31 1998-03-03 E. I. Du Pont De Nemours And Company Herbicidal pyridazinones
DE19540995A1 (de) 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9612884D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
EP0912550A1 (en) 1996-06-25 1999-05-06 Smithkline Beecham Plc Sulfonamide derivatives as 5ht7 receptor antagonists
WO1998023285A1 (en) 1996-11-29 1998-06-04 Smithkline Beecham Plc Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis b
US5939423A (en) 1997-04-16 1999-08-17 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US5994396A (en) 1997-08-18 1999-11-30 Centaur Pharmaceuticals, Inc. Furansulfonic acid derivatives and pharmaceutical compositions containing the same
JP4253126B2 (ja) 1998-01-29 2009-04-08 アムジェン インコーポレイテッド Ｐｐａｒ−ガンマ調節剤
NZ507760A (en) 1998-03-26 2002-10-25 Japan Tobacco Inc Amide derivatives and nociceptin antagonists
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
TR200501553T2 (tr) 1999-01-15 2005-06-21 Altana Pharma Ag PDE-IV inhibe edici aktivitesi olan fenilfenantridinler
PL352835A1 (en) 1999-07-16 2003-09-08 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
ES2302697T3 (es) 1999-08-10 2008-08-01 The Chancellor, Masters And Scholars Of The University Of Oxford Compuestos n-alquilicos de cadena larga y derivados oxa de los mismos y uso como composiciones antivirales.
ES2316383T3 (es) 1999-09-17 2009-04-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
AR025884A1 (es) 1999-10-01 2002-12-18 Takeda Pharmaceutical Compuestos de amina ciclica, su produccion y su uso
YU41202A (sh) 1999-12-28 2005-03-15 Pfizer Products Inc. Ne-peptidni inhibitori vezivanja za ćeliju zavisnog od vla-4 korisni pri tretiranju inflamatornih, autoimunih i respiratornih bolesti
AU2882801A (en) 2000-01-28 2001-08-07 Kaken Pharmaceutical Co., Ltd. Azepine derivatives
US6511980B2 (en) 2000-05-05 2003-01-28 Ortho Mcneil Pharmaceutical, Inc. Substituted diamine derivatives useful as motilin antagonists
EP1193268A1 (en) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases
WO2002051410A2 (en) 2000-12-22 2002-07-04 Akzo Nobel N.V. Phenylthiazole and thiazoline derivatives and their use as antiparasitics
US7115595B2 (en) 2000-12-27 2006-10-03 Dainippon Sumitomo Pharma Co., Ltd. Carbapenem compounds
AU2002248418A1 (en) 2001-02-09 2002-08-28 Massachusetts Institute Of Technology Methods of identifying agents that mediate polypeptide aggregation
US6650463B2 (en) 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
NZ528820A (en) 2001-04-19 2007-01-26 Eisai Co Ltd 2-iminopyrrolidine derivatives
KR100713137B1 (ko) 2001-06-28 2007-05-02 동화약품공업주식회사 신규의 2,4-디플루오로벤즈아미드 유도체
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
DE10136043A1 (de) 2001-07-25 2003-02-13 Degussa Verfahren zur Herstellung von modifiziertem Ruß
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
ATE297925T1 (de) 2001-11-20 2005-07-15 Lilly Co Eli 3-substituierte oxindol beta 3 agonisten
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
EP1512396A4 (en) 2002-06-05 2008-12-31 Inst Med Molecular Design Inc HEMMER AGAINST ACTIVATION OF AP-1 AND NFAT
RU2340605C2 (ru) 2002-06-27 2008-12-10 Ново Нордиск А/С Арилкарбонильные производные в качестве терапевтических средств
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
WO2004010943A2 (en) 2002-07-31 2004-02-05 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
AU2003254177A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
US7338956B2 (en) 2002-08-07 2008-03-04 Sanofi-Aventis Deutschland Gmbh Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
EP1541172A1 (en) 2002-08-09 2005-06-15 Ajinomoto Co., Inc. Remedy for intestinal diseases and visceral pain
US20040110802A1 (en) 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
WO2004022060A2 (en) 2002-09-06 2004-03-18 Janssen Pharmaceutica, N.V. (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders
SE0202838D0 (sv) 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
US7378525B2 (en) 2002-12-23 2008-05-27 Millennium Pharmaceuticals, Inc. CCR8 inhibitors
US7320989B2 (en) 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
EP1605752B1 (en) 2003-03-27 2011-09-14 Cytokinetics, Inc. Sulfonamides for the treatment of congestive heart failure, their compositions and uses.
US7329680B2 (en) 2003-04-30 2008-02-12 The Institute For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids
WO2004100947A2 (en) 2003-05-06 2004-11-25 Smithkline Beecham Corporation Novel chemical compounds
WO2004101562A2 (en) 2003-05-13 2004-11-25 Schering Corporation Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors
EP1651595A2 (en) 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US20110275630A1 (en) 2003-06-02 2011-11-10 Abbott Laboratories Isoindolinone kinase inhibitors
JP2006527201A (ja) 2003-06-06 2006-11-30 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体アンタゴニスト
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
GB0319151D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
US8084457B2 (en) 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US7498050B2 (en) 2003-12-15 2009-03-03 Kraft Foods Global Brands Llc Edible spread composition and packaged product
DE102004009238A1 (de) 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
WO2005087217A1 (en) 2004-03-05 2005-09-22 The General Hospital Corporation Compositions and methods for modulating interaction between polypeptides
US20080113944A1 (en) 2004-05-04 2008-05-15 Novo Nordisk A/S Novel Indole Derivatives
US20090105218A1 (en) 2004-05-29 2009-04-23 7Tm Pharma A/S CRTH2 Receptor Ligands For Therapeutic Use
MX2007000015A (es) 2004-06-22 2007-03-07 Schering Corp Ligandos de receptor de canabinoide.
CA2573426C (en) 2004-07-30 2015-11-17 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents
CA2577275A1 (en) 2004-08-31 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
DE102004042441A1 (de) 2004-08-31 2006-04-06 Sanofi-Aventis Deutschland Gmbh Mit Aminosäuren substituierte Hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2008515986A (ja) * 2004-10-13 2008-05-15 ワイス Ｎ−ベンゼンスルホニル置換アニリノ−ピリミジン類似物
EP2275412A1 (en) 2004-10-19 2011-01-19 Novartis Vaccines and Diagnostics, Inc. Indole and benzimidazole derivatives
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
US20060122236A1 (en) 2004-12-06 2006-06-08 Wood Michael R Substituted biaryl-carboxylate derivatives
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
CN101128454A (zh) 2004-12-22 2008-02-20 阿斯利康(瑞典)有限公司 用作抗癌药物的吡啶羧酰胺衍生物
FI117653B (fi) 2005-02-21 2006-12-29 Eigenor Oy Menetelmä ja laitteisto liikkuvien kohteiden havaitsemiseksi tutkalla
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
EP1940786B1 (en) 2005-09-16 2010-08-18 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
CA2633541A1 (en) 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(6-membered aromatic ring)-amido anti-viral compounds
AU2006331770A1 (en) 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist
EP1981849A1 (en) 2005-12-29 2008-10-22 LEK Pharmaceuticals D.D. Heterocyclic compounds
EP2019830A4 (en) 2006-05-04 2011-01-19 Inst Hepatitis & Virus Res INHIBITORS OF THE SECRETION OF HEPATITIS B VIRUS ANTIGENS FOR THE TREATMENT OF A CHRONIC HEPATITIS VIRUS
US20080021063A1 (en) 2006-07-18 2008-01-24 Kazantsev Aleksey G Compositions and methods for modulating sirtuin activity
US8153803B2 (en) 2006-07-18 2012-04-10 The General Hospital Corporation Compositions and methods for modulating sirtuin activity
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
WO2008022171A1 (en) 2006-08-17 2008-02-21 Boehringer Ingelheim International Gmbh Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors
CA2665007A1 (en) 2006-10-06 2008-05-08 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
WO2008076270A2 (en) 2006-12-13 2008-06-26 Temple University-Of The Commonwealth System Of Higher Education Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
US20100022517A1 (en) 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
JP2008179621A (ja) 2006-12-28 2008-08-07 Taisho Pharmaceutical Co Ltd 含窒素飽和複素環化合物
JP2008184403A (ja) 2007-01-29 2008-08-14 Japan Health Science Foundation 新規ｃ型肝炎ウイルス阻害剤
CA2681162C (en) 2007-03-15 2015-11-24 Novartis Ag Benzyl and pyridine derivatives as modulators of hedgehog pathway
US8097728B2 (en) 2007-04-30 2012-01-17 Philadelphia Health & Education Corporation Iminosugar compounds with antiflavirus activity
EA019524B1 (ru) 2007-05-04 2014-04-30 Айрм Ллк СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ с-kit И PDGFR
WO2008154819A1 (fr) 2007-06-18 2008-12-24 Zhang, Zhongneng Thiazolyl-dihydropyrimidines à substitution carbéthoxy
US8597949B2 (en) 2007-07-28 2013-12-03 The University Of Chicago Methods and compositions for modulating RAD51 and homologous recombination
PT2170900E (pt) 2007-08-01 2013-01-24 Sigma Tau Ind Farmaceuti Forma cristalina ii de 7-(dimetoximetil)-camptotecina, sua utilização como intermediário e produtos obtidos a partir dela
CN101765425A (zh) 2007-08-02 2010-06-30 弗·哈夫曼-拉罗切有限公司 苯甲酰胺衍生物用于治疗cns障碍的用途
CN101429166B (zh) 2007-11-07 2013-08-21 上海特化医药科技有限公司 喹唑啉酮衍生物及其制备方法和用途
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
FR2926555B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives bicycliques de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926554B1 (fr) 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
FR2926553B1 (fr) 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
CU20080028A6 (es) 2008-02-29 2011-02-24 Ct Ingenieria Genetica Biotech Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus
WO2009146013A1 (en) 2008-03-31 2009-12-03 Georgetown University Myosin light chain phosphatase inhibitors
ES2527589T3 (es) 2008-04-24 2015-01-27 Msd K.K. Inhibidor de la enzima de elongación de ácidos grasos de cadena larga que comprende un derivado de arilsulfonilo como principio activo
US20090325959A1 (en) 2008-06-26 2009-12-31 Vittitow Jason L Method for treating ophthalmic diseases using rho kinase inhibitor compounds
US20090325960A1 (en) 2008-06-26 2009-12-31 Fulcher Emilee H Method for treating inflammatory diseases using rho kinase inhibitor compounds
US8410147B2 (en) 2008-06-26 2013-04-02 Inspire Pharmaceuticals, Inc. Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds
US20100008968A1 (en) 2008-06-26 2010-01-14 Lampe John W Method for treating cardiovascular diseases using rho kinase inhibitor compounds
US8207195B2 (en) 2008-06-26 2012-06-26 Inspire Pharmaceuticals, Inc. Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
WO2009158587A1 (en) 2008-06-26 2009-12-30 Inspire Pharmaceuticals, Inc. Method for treating pulmonary diseases using rho kinase inhibitor compounds
EP2321268A2 (en) 2008-08-15 2011-05-18 F. Hoffmann-La Roche AG Bi-aryl aminotetralines
WO2010027996A1 (en) 2008-09-02 2010-03-11 Institute For Hepatitis And Virus Research Novel imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity
US8143269B2 (en) 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
WO2010043592A1 (en) 2008-10-15 2010-04-22 Revotar Biopharmaceuticals Ag Lipase inhibitors for use for the treatment of obesity
AR074199A1 (es) 2008-11-20 2010-12-29 Glaxosmithkline Llc Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer.
US20100204210A1 (en) 2008-12-04 2010-08-12 Scott Sorensen Method for treating pulmonary diseases using rho kinase inhibitor compounds
US8273754B2 (en) 2008-12-30 2012-09-25 Arqule, Inc. Substituted 1H-pyrazolo[3,4-D]pyrimidine-6-amine compounds
WO2010088000A2 (en) 2009-02-02 2010-08-05 Angion Biomedica Corp. Antifibrotic compounds and uses thereof
WO2010123139A1 (ja) 2009-04-24 2010-10-28 持田製薬株式会社 スルファモイル基を有するアリールカルボキサミド誘導体
ES2536278T3 (es) 2009-05-19 2015-05-22 Bayer Intellectual Property Gmbh Arilpirrolinas insecticidas
MX373926B (es) 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
WO2011002635A1 (en) 2009-06-30 2011-01-06 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011035143A2 (en) 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Methods and compositions for inhibiting rho-mediated diseases and conditions
WO2011058766A1 (en) 2009-11-16 2011-05-19 Raqualia Pharma Inc. Aryl carboxamide derivatives as ttx-s blockers
CN102093320B (zh) 2009-12-09 2013-08-28 扬子江药业集团上海海尼药业有限公司 一种可溶性环氧化物水解酶抑制剂
WO2011088015A1 (en) 2010-01-15 2011-07-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2011088561A1 (en) 2010-01-20 2011-07-28 University Of Manitoba Anti-viral compounds and compositions
US20130045203A1 (en) 2010-03-02 2013-02-21 Emory University Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP
CN102906080A (zh) 2010-03-11 2013-01-30 百时美施贵宝公司 治疗丙型肝炎的化合物
CN102206172B (zh) * 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
US20130018039A1 (en) 2010-03-31 2013-01-17 Bodmer Vera Q Imidazolyl-imidazoles as kinase inhibitors
EA023788B1 (ru) 2010-05-07 2016-07-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Производные индола и фармацевтические композиции на их основе
WO2011155898A1 (en) 2010-06-11 2011-12-15 Wadell Goeran New antiviral compounds
WO2011163593A2 (en) 2010-06-25 2011-12-29 Philadelphia Health & Education Corporation D/B/A Drexel Induction of immune response
JP2013531063A (ja) 2010-07-19 2013-08-01 インスパイアー ファーマシューティカルズ，インコーポレイティド 二官能基Ｒｈｏキナーゼ阻害化合物、組成物およびその使用
JP2013536178A (ja) 2010-07-26 2013-09-19 ニューロセラピューティクス ファーマ， インコーポレイテッド アリールスルホンアミド誘導体、組成物、および使用方法
EP2597953A4 (en) 2010-07-27 2013-12-25 Inspire Pharmaceuticals Inc METHOD FOR THE TREATMENT OF EYE DISEASES USING KINASE-INHIBITOR COMPOUNDS IN PRODRUG FORMS
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
WO2012033956A1 (en) 2010-09-08 2012-03-15 Mithridion, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
US8921381B2 (en) 2010-10-04 2014-12-30 Baruch S. Blumberg Institute Inhibitors of secretion of hepatitis B virus antigens
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
ES2585396T3 (es) 2010-12-02 2016-10-05 VIIV Healthcare UK (No.5) Limited Alquilamidas como inhibidores de la unión del VIH
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
GB201103419D0 (2) 2011-02-28 2011-04-13 Univ Aberdeen
PT3590928T (pt) 2011-04-08 2021-08-19 Janssen Sciences Ireland Unlimited Co Derivados de pirimidina para o tratamento de infeções virais
US8889716B2 (en) 2011-05-10 2014-11-18 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
JP5977347B2 (ja) * 2011-07-01 2016-08-24 バルーク エス．ブルームバーグ インスティテュート Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体
BR112014015197A8 (pt) 2011-12-21 2017-06-13 Novira Therapeutics Inc agentes antivirais de hepatite b
EP2800742B1 (en) 2012-01-06 2016-04-06 Janssen Sciences Ireland UC 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis b
BR112014021498A2 (pt) 2012-02-29 2017-07-18 Institute For Hepatitis And Virus Res composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
US20130267517A1 (en) 2012-03-31 2013-10-10 Hoffmann-La Roche Inc. Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
ES2575398T3 (es) 2012-03-31 2016-06-28 F. Hoffmann-La Roche Ag 4-Metil-dihidropirimidinas novedosas para el tratamiento y la profilaxis de la infección por el virus de la hepatitis B
MX2014014323A (es) 2012-05-25 2015-02-12 Janssen R & D Ireland Nucleosidos de espirooxetano de uracilo.
AU2013267209B2 (en) 2012-06-01 2017-02-02 Baruch S. Blumberg Institute Modulation of hepatitis B virus cccDNA transcription
JO3300B1 (ar) 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
TW201408652A (zh) 2012-07-11 2014-03-01 Hoffmann La Roche 作爲ＲＯＲｃ調節劑之芳基磺內醯胺衍生物
KR102271574B1 (ko) 2012-08-28 2021-07-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
EA026957B1 (ru) 2012-08-28 2017-06-30 Янссен Сайенсиз Айрлэнд Юси Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
CA2881322A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
BR112015015584A2 (pt) 2012-12-27 2017-12-12 Baruch S Blumberg Inst novos agentes antivirais contra infecção por hbv
WO2014131847A1 (en) 2013-02-28 2014-09-04 Janssen R&D Ireland Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
JP5654715B1 (ja) 2013-02-28 2015-01-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 テトラヒドロイミダゾ［１，５−ｄ］［１，４］オキサゼピン誘導体（ＴＥＴＲＡＨＹＤＲＯＩＭＩＤＡＺＯ［１，５−ｄ］［１，４］ＯＸＡＺＥＰＩＮＥＤＥＲＩＶＡＴＩＶＥ）
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX353412B (es) 2013-04-03 2018-01-10 Janssen Sciences Ireland Uc Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
TWI733288B (zh) 2013-05-17 2021-07-11 愛爾蘭商健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
BR112015028873A2 (pt) 2013-05-17 2017-07-25 Hoffmann La Roche heteroaril-diidro-pirimidinas interligados na posição 6, para o tratamento e profilaxia de infecção pelo vírus da hepatite b
DK2997019T3 (en) 2013-05-17 2018-12-03 Janssen Sciences Ireland Uc SULFAMOYLTHIOPHENAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
PE20160026A1 (es) 2013-05-28 2016-02-03 Bayer Cropscience Ag Compuestos heterociclicos como agentes para control de plagas
UY35590A (es) 2013-05-28 2014-11-28 Astrazeneca Ab Nuevos compuestos para el tratamiento del cáncer
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
HRP20180791T1 (hr) 2013-07-25 2018-09-07 Janssen Sciences Ireland Uc Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
WO2015055764A1 (en) 2013-10-18 2015-04-23 Syngenta Participations Ag 3-methanimidamid-pyridine derivatives as fungicides
WO2015057945A1 (en) 2013-10-18 2015-04-23 Indiana University Research And Technology Corporation Hepatitis b viral assembly effectors
CA2923712C (en) 2013-10-23 2021-11-02 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2015073774A1 (en) 2013-11-14 2015-05-21 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis b infections
JO3466B1 (ar) 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
RU2692258C2 (ru) 2014-01-31 2019-06-24 Когнишн Терапьютикс, Инк. Композиции изоиндолина и способы лечения нейродегенеративного заболевания
CA2936947A1 (en) 2014-02-05 2015-08-13 Novira Therapeutics, Inc. Combination therapy for treatment of hbv infections
TW201620893A (zh) 2014-02-06 2016-06-16 健生科學愛爾蘭無限公司 磺醯胺基吡咯醯胺衍生物及其用作治療ｂ型肝炎之醫藥品的用途
AU2015226206B2 (en) 2014-03-07 2017-03-16 F. Hoffmann-La Roche Ag Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
ES2748029T3 (es) 2014-03-13 2020-03-12 Univ Indiana Res & Tech Corp Moduladores alostéricos de proteína núcleo de hepatitis B
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
CN104945395B (zh) 2014-03-28 2018-01-23 广东东阳光药业有限公司 二氢嘧啶类化合物及其在药物中的应用
CN106459061B (zh) 2014-05-30 2020-01-21 齐鲁制药有限公司 作为hbv抑制剂的二氢嘧啶并环衍生物
CN107406378A (zh) 2014-12-02 2017-11-28 诺维拉治疗公司 用于hbv治疗的硫化烷基化合物和吡啶类反式磺酰胺化合物
WO2016109684A2 (en) 2014-12-30 2016-07-07 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis b infections
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
JP2018510159A (ja) 2015-03-19 2018-04-12 ノヴィラ・セラピューティクス・インコーポレイテッド アゾカン及びアゾナン誘導体及びｂ型肝炎感染症の治療法
US10442788B2 (en) 2015-04-01 2019-10-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
CA2982811A1 (en) 2015-04-17 2016-10-20 Indiana University Research And Technology Corporation Hepatitis b viral assembly effectors
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
TW201718496A (zh) 2015-09-29 2017-06-01 諾維拉治療公司 B型肝炎抗病毒劑之晶型
EP3246283B1 (en) 2016-05-17 2019-09-18 KONE Corporation An elevator door panel
CN109251212A (zh) 2017-07-14 2019-01-22 上海长森药业有限公司 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途

Also Published As

Publication number Publication date
EA027194B1 (ru) 2017-06-30
AU2014222641A1 (en) 2015-08-13
HUE034820T2 (en) 2018-02-28
CA2899706A1 (en) 2014-09-04
IL240213A0 (en) 2015-09-24
MX2015011229A (es) 2016-02-03
CA2899706C (en) 2021-10-19
MX366123B (es) 2019-06-27
SI2961732T1 (sl) 2017-07-31
JP2016515096A (ja) 2016-05-26
EA201591586A1 (ru) 2015-12-30
US10125094B2 (en) 2018-11-13
JP6466348B2 (ja) 2019-02-06
WO2014131847A1 (en) 2014-09-04
US20190077749A1 (en) 2019-03-14
IL240213A (en) 2016-10-31
EP2961732B1 (en) 2017-04-12
EP2961732A1 (en) 2016-01-06
HRP20170945T1 (hr) 2017-09-22
AU2014222641B2 (en) 2018-03-15
DK2961732T3 (en) 2017-07-10
US20160002155A1 (en) 2016-01-07
CN105189453B (zh) 2018-04-10
HK1218110A1 (zh) 2017-02-03
US10941113B2 (en) 2021-03-09
CN105189453A (zh) 2015-12-23
BR112015020242A2 (pt) 2017-07-18
ES2628953T3 (es) 2017-08-04
PT2961732T (pt) 2017-06-26

Similar Documents

Publication Publication Date Title
IL264541B (en) The history of sulfamoylpyrrolamide and their use as drugs to treat jaundice b
IL240213A0 (en) Sulfamoyl-arylamides and their use as drugs for the treatment of jaundice b
IL242141B (en) The history of sulfamoylthiophenamide and their use as drugs to treat jaundice b
IL241110A0 (en) n-phenyl-carboxamide derivatives and their use as drugs for the treatment of type b jaundice
IL253225A0 (en) Sulfamoyl-arylamides and their use as drugs to treat jaundice b
IL244486A0 (en) Carboxamide history and their use as drugs to treat jaundice b
IL243410B (en) The history of glyoxamide-converted pyrrolamide and their use as drugs for the treatment of hepatitis b
AP2015008814A0 (en) Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b